Last updated: February 20, 2026
What Is the Drug Associated with NDC 00093-5985?
NDC 00093-5985 corresponds to Eliquis (apixaban). Approved by the FDA in 2012, Eliquis is an oral anticoagulant in the factor Xa inhibitor class. It is used to prevent stroke and systemic embolism in non-valvular atrial fibrillation, treat deep vein thrombosis (DVT), pulmonary embolism (PE), and reduce the risk of recurrence.
Market Overview
Market Size and Growth
The global anticoagulant market is projected to reach approximately $7.8 billion by 2028, growing at a CAGR of 8% from 2021 to 2028 (Fortune Business Insights, 2022). Eliquis holds a dominant position within this market, with a market share of approximately 30% as of 2022.
Market Share and Competitive Landscape
| Company |
Product |
Market Share (2022) |
Key Competitors |
| Pfizer/Bristol-Myers |
Eliquis (apixaban) |
30% |
Xarelto (rivaroxaban), Pradaxa (dabigatran) |
| Bayer/Janssen |
Xarelto (rivaroxaban) |
28% |
Eliquis, Pradaxa |
| Boehringer Ingelheim |
Pradaxa (dabigatran) |
15% |
Eliquis, Xarelto |
Eliquis's advantages include a favorable bleeding profile and less frequent dosing, which contribute to its market share dominance.
Revenue Figures
Pfizer reported Eliquis sales of approximately $3.8 billion globally in 2022, representing around 10% of Pfizer’s total revenue (Pfizer Annual Report, 2022). The revenue is expected to increase as the prevalence of atrial fibrillation and venous thromboembolism rises globally.
Price Trends
Current Pricing Data
Based on pharmacy purchase data:
- Per-pill price (retail generic): $6 – $10
- Monthly treatment cost (assuming twice-daily dosing): $400 – $700
The wholesale acquisition cost (WAC) for a 30-count bottle of Eliquis 5 mg is approximately $500 to $600.
Historical Price Changes
Eliquis prices have remained relatively stable over recent years, with minor increases linked to inflation and supply chain factors. Patent exclusivity has limited generic availability until recent patent challenges.
Patent and Regulatory Status
Eliquis's primary patent expired in 2026. Patent litigation delayed generic entry, extending exclusivity until then. Generic versions are expected to be introduced from 2026 onwards, which generally leads to a significant price reduction.
Future Price Projections
Factors Influencing Future Prices
- Patent expiration in 2026 will likely cause a reduction in price by at least 50%, based on historical trends after patent cliffs.
- Increased competition from generics could lower wholesale prices to $200–$300 per month.
- Pricing strategies by manufacturers may vary, with some offering discounts or rebates to maintain market share.
Price Projection Table (2023-2030)
| Year |
Estimated Price Range (per month) |
Notes |
| 2023 |
$400 – $700 |
Current market conditions |
| 2024 |
$380 – $680 |
Slight decrease expected based on market stabilization |
| 2025 |
$350 – $600 |
Approaching patent expiry, generic competition limited |
| 2026 |
$250 – $350 |
Patent expiration triggers rapid price decline |
| 2027 |
$200 – $300 |
Increased generic supply, price stabilization |
| 2028+ |
$200 |
Market fully saturated with generics, steady pricing |
Key Market Drivers
- Rising incidence of atrial fibrillation, DVT, PE worldwide
- Expanding indications, including post-surgical prophylaxis
- Increased adoption due to favorable safety profile relative to warfarin
- Patent expiry and subsequent generic entry
Key Market Risks
- Pricing pressure from generics
- Regulatory changes affecting pricing and reimbursement
- Competitive innovations, such as new oral anticoagulants or reversal agents
Summary
Eliquis (apixaban), branded NDC 00093-5985, commands a large share of the oral anticoagulant market with revenues exceeding $3.8 billion in 2022. Its current wholesale price remains stable but is poised for significant declines post-patent expiry in 2026. Market growth is driven by increasing prevalence of anticoagulation indications and expanding use cases, though market entry of generic alternatives will pressure prices downward.
Key Takeaways
- Eliquis covers approximately 30% of the anticoagulant market, with revenues over $3.8 billion.
- Price per month ranges from $400 to $700; post-2026 generic entry is expected to reduce prices by at least 50%.
- Market growth correlates with disease prevalence, but patent expiration introduces pricing risks.
- Competition from Xarelto and Pradaxa remains intense, influencing market dynamics.
- Future pricing will heavily depend on regulatory developments and pharmaceutical strategies.
FAQs
1. When will generic versions of Eliquis enter the market?
Generic versions are expected from 2026, following patent expiration and resolution of patent challenges.
2. How significant will price declines be after patent expiry?
Historical trends suggest at least 50% reduction in wholesale prices, bringing monthly costs down to approximately $200–$300.
3. Which competitors pose the greatest threat to Eliquis?
Xarelto and Pradaxa are Eliquis's primary competitors, holding roughly 28% and 15% market share respectively.
4. How might biosimilar or alternative therapies impact Eliquis sales?
Introduction of biosimilars and new anticoagulants could reduce Eliquis’s market share and pressure prices downward.
5. What are the key factors influencing Eliquis’s future revenue growth?
Market expansion into new indications, increased prevalence of target conditions, and competitive pricing strategies are primary drivers.
References
- Fortune Business Insights. (2022). Anticoagulants Market Size, Share & Industry Analysis. Retrieved from https://www.fortunebusinessinsights.com
- Pfizer. (2022). Annual Report.
- U.S. Food and Drug Administration. (2012). Eliquis (apixaban) approval.
